A controlled inflammatory response is beneficial when providing protection against infection;however dysregulated excessive inflammation contributes to disease pathogenesis in arthritis, cancer, cardiovascular disease, and a host of autoimmune conditions. This research project focuses on the role of the shed form of low density lipoprotein receptor related protein (sLRP-1) in inflammation. Our long-term goal is to understand the anti-inflammatory role of sLRP-1 in vivo and describe the mechanisms by which sLRP-1 is shed from the cell surface during inflammation. LRP-1 is a member of the LDL receptor gene family, which includes type I trans-membrane proteins that function in receptor-mediated endocytosis and cell signaling. Mature form of LRP-1 includes the 515 kDa a-chain and 85 kDa transmembrane p-chain. Shed form of LRP-1, which is detected in circulation, contains the a-chain (515 kDa subunit) and a 55 kDa fragment of the 3-chain. Recent evidence from our lab showed that in a rodent model of peripheral nerve injury, sLRP-1 expressed anti-inflammatory activity that did not result from competition with membrane-anchored LRP-1 for common ligands. In this research proposal we will test our major hypothesis that sLRP-1 exhibits anti- inflammatory biological activity in vivo and may represent a novel endogenous anti-inflammatory factor. In this application three specific aims are proposed.
In Aim 1, we propose to elucidate the mechanism of LRP- 1 shedding and identify the protease responsible for this process.
Aim 2 builds on preliminary data in which we have demonstrated that sLRP-1 accumulates in circulation during LPS-induced inflammation. We will continue these studies so we can understand how LPS challenge regulates accumulation of sLRP-1 in plasma in wild-type mice. Studies will also be conducted to test whether sLRP-1 in circulation is primarily blood cells originated.
In Aim 3, we will determine whether endogenously-produced and exogenously- administered sLRP-1 regulates development of inflammation in response to LPS. Understanding the physiological significance of sLRP-1 accumulation in blood during inflammation and sLRP-1 anti- inflammatory potential are the critical objectives. Additionally, we will perform pharmacologic characterization of sLRP-1 in circulation in vivo. Studies will be made to determine parameters such as plasma half-life, distribution half-life, and organ biodistribution of sLRP-1 that are essential for the development of any pharmaceutical. This project will contribute to our understanding of the pathophysiology of inflammation and provide critical information regarding how sLRP-1 may represent a novel endogenous anti-inflammatory factor.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F07-K (20))
Program Officer
Meadows, Tawanna
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code